Esophageal Cancer: Current Advances and Controversies

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sandra Starnes, MD
Inderpal Sarkaria, MD

Presentations

  1. Endoscopic Therapy for Early-Stage Esophageal Cancer
    Robert Van Haren, MD, MSPH
     
  2. Optimal Treatment for Esophageal Adenocarcinoma: CROSS
    Monisha Sudarshan, MD MPH
    Disclosure(s): Ethicon Johnson & Johnson: Advisory Board (Terminated, June 3, 2024)
     
  3. Optimal Treatment for Esophageal Adenocarcinoma: FLOT
    Jonathan Cools-Lartigue, MD, PhD
     
  4. Panel Discussion
     
  5. Surveillance Versus Resection Following Induction Therapy for Esophageal Cancer
    Biniam Kidane, MD MSc FRCSC
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Unrestricted Educational grant (Ongoing); Merck: Advisory Board (Terminated, January 1, 2023), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2023); Olympus: Consultant (Ongoing); Roche: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  6. Emerging Biomarkers in Esophageal Cancer (MSI/MMR, HER2, PDL) and Implications For Treatment
    Daniela Molena, MD
    Disclosure(s): Boehringer: Consultant (Terminated, February 21, 2024)
     
  7. Panel Discussion
     
  8. Esophagectomy vs. Gastrectomy for Gastroesophageal Junction Tumors
    Stephanie G. Worrell, MD
    Disclosure(s): Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  9. Open Esophagectomy: Tips and Techniques
    Richard J. Battafarano, MD PhD
     
  10. RAMIE Tips and Tricks: Is RAMIE the Preferred Approach? Update on Trials
    Lana Schumacher, MD, MS, FACS
    Disclosure(s): Medtronic: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); DaVinci Intuitive Surgical: Consultant (Ongoing)
     
  11. Panel Discussion
     
  12. Post-Esophagectomy Diet Management: Early Esophagram and Diet Advancement
    Luis F. Tapias, MD
    Disclosure(s): AstraZeneca: Advisory Board (Terminated, January 31, 2024); Intuitive Surgical: Consultant (Terminated, December 31, 2023)
     
  13. Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Three-Year National Perspective
    Sara Sakowitz, MS, MPH
Activity summary
Available credit: 
  • 2.00 ABS Accredited CME
  • 2.00 ABTS Accredited CME
  • 2.00 AMA PRA Category 1 Credit
Activity opens: 
03/01/2025
Activity expires: 
03/01/2028
Cost:
$0.00
Rating: 
0

Available Credit

  • 2.00 ABS Accredited CME
  • 2.00 ABTS Accredited CME
  • 2.00 AMA PRA Category 1 Credit

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sandra Starnes, MD
Inderpal Sarkaria, MD

Presentations

  1. Endoscopic Therapy for Early-Stage Esophageal Cancer
    Robert Van Haren, MD, MSPH
     
  2. Optimal Treatment for Esophageal Adenocarcinoma: CROSS
    Monisha Sudarshan, MD MPH
    Disclosure(s): Ethicon Johnson & Johnson: Advisory Board (Terminated, June 3, 2024)
     
  3. Optimal Treatment for Esophageal Adenocarcinoma: FLOT
    Jonathan Cools-Lartigue, MD, PhD
     
  4. Panel Discussion
     
  5. Surveillance Versus Resection Following Induction Therapy for Esophageal Cancer
    Biniam Kidane, MD MSc FRCSC
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Unrestricted Educational grant (Ongoing); Merck: Advisory Board (Terminated, January 1, 2023), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2023); Olympus: Consultant (Ongoing); Roche: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  6. Emerging Biomarkers in Esophageal Cancer (MSI/MMR, HER2, PDL) and Implications For Treatment
    Daniela Molena, MD
    Disclosure(s): Boehringer: Consultant (Terminated, February 21, 2024)
     
  7. Panel Discussion
     
  8. Esophagectomy vs. Gastrectomy for Gastroesophageal Junction Tumors
    Stephanie G. Worrell, MD
    Disclosure(s): Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  9. Open Esophagectomy: Tips and Techniques
    Richard J. Battafarano, MD PhD
     
  10. RAMIE Tips and Tricks: Is RAMIE the Preferred Approach? Update on Trials
    Lana Schumacher, MD, MS, FACS
    Disclosure(s): Medtronic: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); DaVinci Intuitive Surgical: Consultant (Ongoing)
     
  11. Panel Discussion
     
  12. Post-Esophagectomy Diet Management: Early Esophagram and Diet Advancement
    Luis F. Tapias, MD
    Disclosure(s): AstraZeneca: Advisory Board (Terminated, January 31, 2024); Intuitive Surgical: Consultant (Terminated, December 31, 2023)
     
  13. Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Three-Year National Perspective
    Sara Sakowitz, MS, MPH